BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

Inclusion Criteria: * Healthy volunteers and patients awaiting solid organ transplantation (SOT) must have at least one allele for HLA-B\*08:01 * Subjects can be Epstein-Barr virus (EBV) seronegative or seropositive * Subjects must be seronegative for HIV * Subjects must be seronegative for hepatitis B and C * Have baseline chemistry and hematology (hemoglobin, white blood cells, absolute neutrophil count, eosinophils) within normal limits * Prothrombin time (PT) and partial thromboplastin time (PTT) below the upper limit of normal * Platelets above the lower limit of normal (LLN) * Basophils, lymphocytes, and monocytes must be within 1.2 x upper limit of normal (ULN) or 0.8 x LLN and considered not clinically significant by the investigator * Total creatine kinase (CK) laboratory values \< 1.25 x the upper limit of normal (according to the normal reference ranges of the Ohio State University \[OSU\] laboratory) at baseline (screening \& pre-study visit) and considered not clinically significant by the investigator * Subjects must not be taking antiviral therapy * Must be ≥ 18 years of age and ≤ 65 years of age and willing to either use an effective method of contraception or abstain from sexual activity for at least 3 months following the last dose of vaccination * Female of childbearing potential must have a negative serum pregnancy test prior to the first study drug/placebo (PBS) administration * Agree not to receive any other investigational drug while enrolled in this s…